|
| N = 3675 |
| 平均年龄 | 63.7岁 |
| 年龄分组 |
|
| <60岁 | 1197 (32.6%) |
| ≥60岁 | 2478 (67.4%) |
| 性别 |
|
| 女性 | 1855 (50.5%) |
| 男性 | 1820 (49.5%) |
| 种族 |
|
| 白人 | 2844 (77.4%) |
| 黑人 | 434 (11.8%) |
| 美洲印第安人/阿拉斯加土著民族 | 16 (0.4%) |
| 亚洲人或太平洋岛民 | 360 (9.8%) |
| 未知 | 21 (0.6%) |
| 原发部位 |
|
| 腺头癌 | 2298 (62.5%) |
| 胰体癌 | 553 (15.1%) |
| 胰尾癌 | 824 (22.4%) |
| 病理分级 |
|
| Grade I | 1243 (33.8%) |
| Grade II | 1443 (39.3%) |
| Grade III | 928 (25.3%) |
| Grade IV | 61 (16.6%) |
| 临床分期 |
|
| IA | 720 (19.6%) |
| IB | 827 (22.5%) |
| IIA | 1746 (47.5%) |
| III | 382 (10.4%) |
| T分期 |
|
| T1 | 720 (19.6%) |
| T2 | 827 (22.5%) |
| T3 | 1746 (47.5%) |
| T4 | 382 (10.4%) |
| 胰腺癌生存期 |
|
| 5年生存期 | 1619 (44.1%) |
| 总生存期 | 1539 (41.9%) |
| 胰腺癌特异生存期 |
|
| 5年生存期 | 1801 (49.0%) |
| 总生存期 | 1743 (47.4%) |